DEPARTMENT OF CARDIOLOGY

UHID / IP NO	40000881 (778)	RISNo./Status:	4001031/
Patient Name:	Mr. GAURAV BAHLAN	Age/Gender:	29 Y/M
Referred By:	Dr. DIWANSHU KHATANA	Ward/Bed No:	OPD
Bill Date/No:	20/02/2023 11:09AM/ OPSCR22-23/3	Scan Date:	
Report Date:	20/02/2023 12:30PM	Company Name:	Provisional

REFERRAL REASON: - WELLNESS PACKAGE

2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

M MODE DIMENSIONS: -

Normal Normal							
IVSD	10.4	6-12mm		LVIDS	31.7	20-40mm	
LVIDD	49.4		32-57mm		LVPWS	18.1	mm
LVPWD	11.3		6-12	2mm	AO	29.9	19-37mm
IVSS	18.1		m	ım	LA	34.0	19-40mm
LVEF	64-66		>5	5%	RA	-	mm
	<u>DOPPLEI</u>	R MEA	SUREN	MENTS & C	ALCULATIONS	<u>S:</u>	
STRUCTURE	MORPHOLOGY	7	VELOC:	ITY (m/s)	GRADI	ENT	REGURGITATION
		<u> </u>		(mmł	<u>Ig)</u>		
MITRAL	NORMAL	E	0.82	e'			NIL
VALVE		A	0.71	E/e'			
TRICUSPID	NORMAL	E 0.47		_		NIL	
VALVE		A 0.41					
AORTIC	NORMAL	1.04				NIL	
VALVE				-			
PULMONARY VALVE	NORMAL	0.67		-		NIL	

COMMENTS & CONCLUSION: -

- NO RWMA, LVEF 64-66%
- NORMAL LV DIASTOLIC FUNCTIONS
- ALL CARDIAC VALVES ARE NORMAL
- ALL CARDIAC CHAMBERS ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS

DR ROOPAM SHARMA
MBBS, PGDCC, FIAE
CONSULTANT \$ INCHARGE
EMERGENCY, PREVENTIVE CARDIOLOGY AND WELLNESS CENTER.

Patient Name Mr. GAURAV BAHLAN Lab No 4001031 UHID 40000881 **Collection Date** 20/02/2023 12:41PM 20/02/2023 12:45PM Age/Gender 29 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 20/02/2023 4:50PM

Referred By Dr. DIWANSHU KHATANA Report Status Final

Mobile No. 8824444010

BIOCHEMISTRY

 Test Name
 Result
 Unit
 Biological Ref. Range

 BLOOD GLUCOSE (FASTING)
 Sample: Fl. Plasma

 BLOOD GLUCOSE FASTING
 113.9

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

BLOOD GLUCOSE (PP) Sample: PLASMA

BLOOD GLUCOSE (PP) 197.3 mg/dl Non – Diabetic: - < 140 mg/dl

Pre – Diabetic: - 140-199 mg/dl Diabetic: - >=200 mg/dl

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

THYROID T3 T4 TSH Sample: Serum

Т3	1.61	ng/mL	0.970 - 1.690
T4	8.60	ug/dl	5.53 - 11.00
TSH	2.832	μIU/mL	0.40 - 4.05

RESULT ENTERED BY : NEETU SHARMA

Dr. MUDITA SHARMA

Patient Name	Mr. GAURAV BAHLAN	Lab No	4001031
UHID	40000881	Collection Date	20/02/2023 12:41PM
Age/Gender	29 Yrs/Male	Receiving Date Report Date	20/02/2023 12:45PM
IP/OP Location	O-OPD	Report Status	20/02/2023 4:50PM
Referred By	Dr. DIWANSHU KHATANA		Final
Mobile No.	8824444010		

BIOCHEMISTRY

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

 $Interpretation: -The \ determination \ of \ T3 \ is \ utilized \ in \ the diagnosis \ of \ T3-hyperthyroidism \ the \ detection \ of \ early \ stages \ of hyperthyroidism \ and \ for \ indicating \ a \ diagnosis \ of \ thyrotoxicosis \ factitia.$

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

24.2

Interpretation:-The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

LFT (LIVER FUNCTION TEST)				Sample: Serum
BILIRUBIN TOTAL	0.64	mg/dl	0.00 - 1.20	
BILIRUBIN INDIRECT	0.47	mg/dl	0.20 - 1.00	
BILIRUBIN DIRECT	0.17	mg/dl	0.00 - 0.40	
SGOT	33.7	U/L	0.0 - 40.0	
SGPT	56.0 H	U/L	0.0 - 40.0	
TOTAL PROTEIN	7.81	g/dl	6.6 - 8.7	
ALBUMIN	4.54	g/dl	3.5 - 5.2	
GLOBULIN	3.3		1.8 - 3.6	
ALKALINE PHOSPHATASE	248.3 H	U/L	53 - 128	
A/G RATIO	1.4 L	Ratio	1.5 - 2.5	

U/L

10.0 - 55.0

RESULT ENTERED BY : NEETU SHARMA

Dr. MUDITA SHARMA

GGTP

 Patient Name
 Mr. GAURAV BAHLAN
 Lab No
 4001031

 UHID
 40000881
 Collection Date
 20/02/2023

 UHID
 40000881
 Collection Date
 20/02/2023 12:41PM

 Age/Gender
 29 Yrs/Male
 Receiving Date
 20/02/2023 12:45PM

 IP/OP Location
 O-OPD
 Report Date
 20/02/2023 4:50PM

Referred By Dr. DIWANSHU KHATANA Report Status Final

Mobile No. 8824444010

BIOCHEMISTRY

BILIRUBIN TOTAL :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS: - Method: Biuret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

ALBUMIN: - Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis. nutritional status

cirrhosis, nutritional status.

ALKALINE PHOSPHATASE: - Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE: - Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

LIPID PROFILE

TOTAL CHOLESTEROL

			200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	47.1		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	144.1		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLECTERO VI DI	25	ma/dl	10 50

CHOLESTERO VLDL 35 mg/dl 10 - 50

190

TRIGLYCERIDES 175.0 Normal:-<150 mg/dl

Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl

<200 mg/dl :- Desirable

CHOLESTEROL/HDL RATIO 4.0 %

RESULT ENTERED BY : NEETU SHARMA

Dr. MUDITA SHARMA

Patient Name Mr. GAURAV BAHLAN Lab No 4001031

UHID 40000881 **Collection Date** 20/02/2023 12:41PM 20/02/2023 12:45PM Age/Gender **Receiving Date** 29 Yrs/Male **Report Date IP/OP Location** O-OPD 20/02/2023 4:50PM

Referred By Dr. DIWANSHU KHATANA **Report Status** Final

Mobile No. 8824444010

BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease. LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are

synthesized in the liver.
CHOLESTEROL VLDL: - Method: VLDL Calculative

Interpretation: -High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

RENAL PROFILE TEST Sample: Serum

UREA	25.0	mg/dl	16.60 - 48.50
BUN	11.7	mg/dl	6 - 20
CREATININE	0.73	mg/dl	0.60 - 1.10
SODIUM	140.9	mmol/L	136 - 145
POTASSIUM	4.53	mmol/L	3.50 - 5.50
CHLORIDE	101.9	mmol/L	98 - 107
URIC ACID	5.58	mg/dl	3.5 - 7.2
CALCIUM	10.54 H	mg/dl	8.60 - 10.30

RESULT ENTERED BY: NEETU SHARMA arrie .

Dr. MUDITA SHARMA

Patient Name Mr. GAURAV BAHLAN Lab No 4001031

 UHID
 40000881
 Collection Date
 20/02/2023 12:41PM

 Age/Gender
 29 Yrs/Male
 Receiving Date Report Date
 20/02/2023 12:45PM

 IP/OP Location
 0-OPD
 20/02/2023 4:50PM

Referred By Dr. DIWANSHU KHATANA Report Status Final

Mobile No. 8824444010

BIOCHEMISTRY

CREATININE - SERUM :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.

URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake andkidney reabsorption.

POTASSIUM:- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting

renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake, prolonged vomiting and reduced

renal reabsorption as well as forms of acidosisand alkalosis. Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

Sample: WHOLE BLOOD EDTA

HBA1C 5.2 % <5.7% Nondiabetic

5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes

Known Diabetic Patients
< 7 % Excellent Control
7 - 8 % Good Control
> 8 % Poor Control

 ${\tt Method: - High - performance liquid chromatography \ HPLC}$

Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbA1C and mean blood glucose values during the preceding 2 to 3 months.

RESULT ENTERED BY : NEETU SHARMA

Dr. MUDITA SHARMA

Lab No **Patient Name** Mr. GAURAV BAHLAN 4001031 UHID 40000881 **Collection Date** 20/02/2023 12:41PM 20/02/2023 12:45PM Age/Gender **Receiving Date** 29 Yrs/Male **Report Date IP/OP Location** O-OPD 20/02/2023 4:50PM

Referred By Dr. DIWANSHU KHATANA **Report Status** Final

Mobile No. 8824444010

BLOOD BANK INVESTIGATION

Unit **Biological Ref. Range Test Name** Result

"AB" Rh Positive **BLOOD GROUPING**

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

RESULT ENTERED BY: NEETU SHARMA OS GARRA

Dr. MUDITA SHARMA

Patient Name Mr. GAURAV BAHLAN Lab No 4001031 UHID 40000881 **Collection Date** 20/02/2023 12:41PM 20/02/2023 12:45PM Age/Gender **Receiving Date** 29 Yrs/Male **Report Date IP/OP Location** O-OPD 20/02/2023 4:50PM

Referred By Dr. DIWANSHU KHATANA Report Status Final

NIL

Mobile No. 8824444010

CLINICAL PATHOLOGY

Test Name Result Unit **Biological Ref. Range URINE SUGAR (POST PRANDIAL)** Sample: Urine URINE SUGAR (POST PRANDIAL) **NEGATIVE URINE SUGAR (RANDOM)** Sample: Urine **NEGATIVE** URINE SUGAR (RANDOM) **ROUTINE EXAMINATION - URINE** Sample: Urine PHYSICAL EXAMINATION **VOLUME** 20 ml COLOUR PALE YELLOW P YELLOW **APPEARANCE** CLEAR CLEAR **CHEMICAL EXAMINATION** РΗ 5.0 L 5.5 - 7.0 SPECIFIC GRAVITY 1.005 1.016-1.022 **PROTEIN NEGATIVE** NEGATIVE **SUGAR NEGATIVE** NEGATIVE **BILIRUBIN NEGATIVE NEGATIVE BLOOD NEGATIVE KETONES NEGATIVE** NEGATIVE NITRITE **NEGATIVE NEGATIVE** UROBILINOGEN **NEGATIVE** NEGATIVE **NEGATIVE** NEGATIVE LEUCOCYTE MICROSCOPIC EXAMINATION WBCS/HPF 0 - 3 1-2 /hpf RBCS/HPF 0.2 0 - 2 /hpf **EPITHELIAL CELLS/HPF** 1-2 0 - 1 /hpf NIL **CASTS** NIL

NIL

RESULT ENTERED BY : NEETU SHARMA

Dr. MUDITA SHARMA

CRYSTALS

Patient Name Mr. GAURAV BAHLAN Lab No 4001031 UHID 40000881 **Collection Date** 20/02/2023 12:41PM 20/02/2023 12:45PM Age/Gender 29 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 20/02/2023 4:50PM

Referred By Dr. DIWANSHU KHATANA **Report Status** Final

8824444010 Mobile No.

CLINICAL PATHOLOGY

NIL **BACTERIA** NIL **OHTERS** NIL NIL

Methodology:-

Methodology:Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific
Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue
(Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method.
interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

RESULT ENTERED BY: NEETU SHARMA Os come.

Dr. MUDITA SHARMA

Patient Name Mr. GAURAV BAHLAN Lab No 4001031 UHID 40000881 **Collection Date** 20/02/2023 12:41PM 20/02/2023 12:45PM Age/Gender 29 Yrs/Male **Receiving Date** Report Date **IP/OP Location** O-OPD 20/02/2023 4:50PM **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final

Mobile No. 8824444010

HEMATOLOGY

Test Name	Result	Unit	Biological Ref. Range
CBC (COMPLETE BLOOD COUNT)			Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	14.2	g/dl	13.0 - 17.0
PACKED CELL VOLUME(PCV)	44.3	%	40.0 - 50.0
MCV	93.7 H	fl	82 - 92
MCH	30.0	pg	27 - 32
MCHC	32.1	g/dl	32 - 36
RBC COUNT	4.73	millions/cu.mm	4.50 - 5.50
TLC (TOTAL WBC COUNT)	6.73	10^3/ uL	4 - 10
DIFFERENTIAL LEUCOCYTE COUNT			
NEUTROPHILS	63.0	%	40 - 80
LYMPHOCYTE	29.0	%	20 - 40
EOSINOPHILS	1.6	%	1 - 6
MONOCYTES	5.8	%	2 - 10
BASOPHIL	0.6 L	%	1 - 2
PLATELET COUNT	2.40	lakh/cumm	1.500 - 4.500

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.

MCV :- Method:- Calculation bysysmex. MCH: - Method: - Calculation bysysmex.
MCHC: - Method: - Calculation bysysmex.

RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: -Optical Detectorblock based on Flowcytometry. Interpretation: -High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry LYMPHOCYTS : - Method: Optical detectorblock based on FlowcytometryEOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE)

20 H

mm/1st hr

0 - 15

RESULT ENTERED BY: NEETU SHARMA Os garrie.

Dr. MUDITA SHARMA

Patient Name Lab No Mr. GAURAV BAHLAN 4001031 20/02/2023 12:41PM UHID 40000881 **Collection Date** 20/02/2023 12:45PM Age/Gender **Receiving Date** 29 Yrs/Male **Report Date** O-OPD **IP/OP Location** 20/02/2023 4:50PM **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final Mobile No. 8824444010

Method:-Modified Westergrens.
Interpretation:-Increased in infections, sepsis, and malignancy.

RESULT ENTERED BY : NEETU SHARMA

Patient Name Mr. GAURAV BAHLAN Lab No 4001031 UHID 40000881 **Collection Date** 20/02/2023 12:41PM 20/02/2023 12:45PM Age/Gender 29 Yrs/Male **Receiving Date** Report Date O-OPD 20/02/2023 4:50PM IP/OP Location **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final

8824444010

Test Name Result Unit Biological Ref. Range

USG REPORT - ABDOMEN AND PELVIS

LIVER:

Mobile No.

Is normal in size 146 mm and shows diffuse increased echogenicity.

No obvious focal lesion seen. No intra hepatic biliary radical dilatation seen.

GALLBLADDER:

Partially distended with mild apparent wall thickening/pericholecystic fat stranding/fluid. No obvious calculus/polyp/mass seen within.

PANCREAS:

Obscured by vowel gases.

SPLEEN:

Appears normal in size (~ 95mm). and it shows uniform echo texture.

RIGHT KIDNEY:

Right kidney measures 109 x 48 mm.

The shape, size and contour of the right kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation.

No calculi seen.

RESULT ENTERED BY: NEETU SHARMA

Patient Name Mr. GAURAV BAHLAN Lab No 4001031 UHID 40000881 **Collection Date** 20/02/2023 12:41PM 20/02/2023 12:45PM Age/Gender **Receiving Date** 29 Yrs/Male **Report Date IP/OP Location** O-OPD 20/02/2023 4:50PM **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final 8824444010 Mobile No.

USG

LEFT KIDNEY:

Left kidney measures 117 x 52 mm.

The shape, size and contour of the left kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation.

No calculi seen.

URINARY BLADDER:

Is normal in contour. No intra luminal echoes are seen. No calculus or diverticulum is seen.

PROSTATE:

Normal

RIGHT ILIAC FOSSA:

No focal fluid collections seen.

IMPRESSION:

Diffuse grade I fatty liver.

RESULT ENTERED BY : NEETU SHARMA

Dr. RENU JADIYA MBBS, DNB RADIOLOGIST

Page: 12 Of 13

Patient Name Mr. GAURAV BAHLAN Lab No 4001031 UHID 40000881 **Collection Date** 20/02/2023 12:41PM 20/02/2023 12:45PM Age/Gender **Receiving Date** 29 Yrs/Male **Report Date IP/OP Location** O-OPD 20/02/2023 4:50PM **Referred By** Dr. DIWANSHU KHATANA **Report Status** Final Mobile No. 8824444010

X Ray

Test Name Result Unit Biological Ref. Range

X-RAY - CHEST PA VIEW

OBSERVATION:

The trachea is central.

The mediastinal and cardiac silhouette are normal.

Cardiothoracic ratio is normal.

Cardiophrenic and costophrenic angles are normal.

Both hila are normal.

The lung fields are clear.

Bones of the thoracic cage are normal.

Soft tissues of the chest wall are normal.

IMPRESSION:

No significant abnormality seen.

End Of Report

RESULT ENTERED BY : NEETU SHARMA

Dr. RENU JADIYA MBBS, DNB RADIOLOGIST

Page: 13 Of 13